Owners, management and financials
CVR: 39270684
Previous names: Kariya Pharmaceuticals IVS
DKK -32,093,186
Gross profit
Net result: DKK -26,490,250
JUMIKA Holdings ApS (25-33,32%), Thomsen Pharma ApS (5-9,99%)
2 more
CVR · view owners
Christian Hölscher
Board: Ian Rodney Laquian (chair) and 4 members
CVR · view management
Active
Founded 18 January 2018
CVR · view overview
0 employees
CVR · 2025
Owner registered: JUMIKA Holdings ApS
CVR · 25/06/2026
View the full event history
Kariya Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Kariya Pharmaceuticals IVS. The management consists of Christian Hölscher. The board consists of Ian Rodney Laquian (chair), Christian Hölscher, Claus Elsborg Olesen and John Connell. The company's owners include JUMIKA Holdings ApS, Thomsen Pharma ApS and MAC Clinical Research Finance Ltd.. The company has 0 employees (2025). In 2025, the company reported a gross profit of DKK -32,093,186 and a net result of DKK -26,490,250 compared with DKK -2,599,412 the year before. Equity in the 2025 report amounted to DKK -25,206,578.
Virksomhedens formål er forskning og udvikling af lægemidler samt dermed beslægtet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -32.1M | -26.5M | 38.9M | -25.2M | 0 | |
| 202401/01/2024 – 31/12/2024 | -3.6M | -2.6M | 2.3M | 1.3M | 1 | |
| 202301/01/2023 – 31/12/2023 | -10.2M | -8M | 2.1M | -6.4M | 1 | |
| 202201/01/2022 – 31/12/2022 | -13.8M | -14M | 2.2M | -26.7M | 1 | |
| 202101/01/2021 – 31/12/2021 | -2.7M | -3.3M | 1.1M | -12.7M | 1 | |
| 202001/01/2020 – 31/12/2020 | -1.5M | -2.2M | 1.7M | -9.5M | 2 | |
| 201901/01/2019 – 31/12/2019 | -6.3M | -7.3M | 3.2M | -7.3M | 1 | |
| 201818/01/2018 – 31/12/2018 | 0 | 0 | 100 | 100 | - |
Compared to 1.037 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningThe CVR number of Kariya Pharmaceuticals ApS is 39270684.
The owners of Kariya Pharmaceuticals ApS include JUMIKA Holdings ApS, Thomsen Pharma ApS and MAC Clinical Research Finance Ltd..
The management of Kariya Pharmaceuticals ApS consists of Christian Hölscher.
The board of Kariya Pharmaceuticals ApS consists of Ian Rodney Laquian, Christian Hölscher and Claus Elsborg Olesen, with Ian Rodney Laquian as chair.
In 2025, Kariya Pharmaceuticals ApS reported a gross profit of DKK -32,093,186.
Kariya Pharmaceuticals ApS had 0 employees in 2025 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Kariya Pharmaceuticals ApS has published its annual report for 2025. Gross profit came to DKK -32,093,186, and the net result was DKK -26,490,250.
Contact info changed: new website: www.kariyapharma.com (June 30, 2026).
As of June 25, 2026, JUMIKA Holdings ApS is registered as an owner of Kariya Pharmaceuticals ApS with an ownership share of 25%.
As of June 25, 2026, is registered as an owner of Kariya Pharmaceuticals ApS with an ownership share of 20%.
As of June 25, 2026, is registered as an owner of Kariya Pharmaceuticals ApS with an ownership share of 25%.
Contact info changed: new website: www.kariyapharma.com (June 19, 2026).
Kariya Pharmaceuticals ApS has published its annual report for 2024. Gross profit came to DKK -3,624,681, and the net result was DKK -2,599,412.
Kariya Pharmaceuticals ApS has published its annual report for 2023. Gross profit came to DKK -10,223,064, and the net result was DKK -8,022,549.
Kariya Pharmaceuticals ApS has published its annual report for 2022. Gross profit came to DKK -13,798,220, and the net result was DKK -14,005,570.
As of May 3, 2023, John Connell has joined the board of directors of Kariya Pharmaceuticals ApS.
As of April 27, 2023, Claus Elsborg Olesen has joined the board of directors of Kariya Pharmaceuticals ApS.
As of April 27, 2023, Ian Rodney Laquian has joined the board of directors of Kariya Pharmaceuticals ApS.
As of April 27, 2023, Mikael Søndergaard Thomsen has joined the board of directors of Kariya Pharmaceuticals ApS.
As of April 27, 2023, Christian Hölscher has joined the board of directors of Kariya Pharmaceuticals ApS.
Kariya Pharmaceuticals ApS has published its annual report for 2021. Gross profit came to DKK -2,712,238, and the net result was DKK -3,255,075.
As of September 16, 2021, Thomsen Pharma ApS is registered as an owner of Kariya Pharmaceuticals ApS with an ownership share of 5%.
On August 23, 2021, the company changed its name from Kariya Pharmaceuticals IVS to Kariya Pharmaceuticals ApS.
Kariya Pharmaceuticals ApS has published its annual report for 2020. Gross profit came to DKK -1,493,450, and the net result was DKK -2,207,146.
As of November 12, 2020, Christian Hölscher is registered as director of Kariya Pharmaceuticals ApS.
As of November 12, 2020, Ian Rodney Laquian has stepped down as director of Kariya Pharmaceuticals ApS.
Kariya Pharmaceuticals ApS has published its annual report for 2019. Gross profit came to DKK -6,324,847, and the net result was DKK -7,304,278.
Kariya Pharmaceuticals ApS has published its annual report for 2018. Gross profit came to DKK 0, and the net result was DKK 0.
As of January 11, 2019, Ian Rodney Laquian is registered as director of Kariya Pharmaceuticals ApS.
As of November 28, 2018, Ian Rodney Laquian has stepped down as adm. dir. of Kariya Pharmaceuticals ApS.
As of January 18, 2018, Ian Rodney Laquian is registered as adm. dir. of Kariya Pharmaceuticals ApS.
Kariya Pharmaceuticals ApS was founded on January 18, 2018.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Companies in the same industry and area
CVR 36465972
CVR 45436497
CVR 46059220
CVR 41978074
CVR 46543912
